Ticagrelor(tye ka’ grel or)
Brilinta
PREGNANCY CATEGORY C
Drug class
Antiplatelet
Therapeutic Actions
Inhibits platelet activation and aggregation, reversibly interacting with platelet adenosine diphosphate receptors.
Indications
Reduction of the rate of thrombotic CV event in patients with acute coronary syndrome
Contraindications and Cautions
Contraindicated with history of intracranial bleeding, active pathologic bleeding, severe hepatic impairment, pregnancy, lactation.
Use cautiously with moderate hepatic impairment.
Available Forms
Tablets—90 mg
Dosages
Adults
180 mg PO loading dose, then 90 mg PO bid. Should give with a loading dose of aspirin, 325 mg PO, then a daily maintenance dose of aspirin, 75–100 mg PO.
Pharmacokinetics
|
Metabolism: Hepatic; T1/2: 7–9 hr
Distribution: May cross placenta; enters breast milk
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
